TC BIOPHARM (HOLDINGS) PLC Financial Statements (2024 and earlier)
Company Profile
| Business Address |
MAXIM 1 HOLYTOWN, ML1 4WR |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | ||||
| Cash and cash equivalents | ||||
| Prepaid expense | ||||
| Other undisclosed current assets | ||||
| Total current assets: | ||||
| Noncurrent Assets | ||||
| Operating lease, right-of-use asset | ||||
| Property, plant and equipment | ||||
| Intangible assets, net (including goodwill) | ||||
| Intangible assets, net (excluding goodwill) | ||||
| Total noncurrent assets: | ||||
| TOTAL ASSETS: | ||||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities, including: | ||||
| Accounts payable | ||||
| Accrued liabilities | ||||
| Other undisclosed accounts payable and accrued liabilities | ||||
| Derivative instruments and hedges, liabilities | ||||
| Other undisclosed current liabilities | ||||
| Total current liabilities: | ||||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | ||||
| Operating lease, liability | ||||
| Total noncurrent liabilities: | ||||
| Total liabilities: | ||||
| Equity | ||||
| Equity, attributable to parent, including: | ||||
| Common stock | ||||
| Additional paid in capital | ||||
| Accumulated deficit | ||||
| Other undisclosed equity, attributable to parent | ||||
| Total equity: | ||||
| TOTAL LIABILITIES AND EQUITY: | ||||
Income Statement (P&L) (USD)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | ||
|---|---|---|---|
| Operating expenses | |||
| Operating loss: | |||
| Nonoperating income | |||
| Other nonoperating expense | |||
| Loss from continuing operations before income taxes: | |||
| Income tax benefit | |||
| Net loss available to common stockholders, diluted: | |||
Comprehensive Income (USD)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | ||
|---|---|---|---|
| Net loss: | |||
| Comprehensive loss, net of tax, attributable to parent: | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.